Abstract
Inflammatory bowel diseases are a group of chronic, relapsing disorders of the gastrointestinal tract. The initially limited therapy options were significantly expanded with the advent of biologics and small molecules. Biologics and small molecules can be divided into four categories based on their immunologic targets – anti-tumor necrosis factor, anti-interleukin, anti-integrin, and janus kinase pathway inhibitor. Each class of medication functions through a particular mechanism of action that dictates its indications for use, rate of efficacy, and safety profile.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
